With some of RTM Vital Signs technology anchored in IP exclusively licensed from Thomas Jefferson University, the firm is usefully understood as a medical device company focused on supporting the transformation of healthcare from reactive and hospital-centered to preventive, proactive, evidenced-based and person-centered. The core objective of the principals is to achieve real-time sensing, monitoring, and analyzing of critical health information which they judge defines the future of medicine. Currently RTM is developing two devices that address the largest areas of healthcare concern and costs: (1) cardiovascular health (prevention of heart attack, stroke, heart failure, kidney failure, and sudden death) and (2) opioid misuse (prevention of overdose) - these devices are based on proprietary cost-effective monitoring technology that employs sensors and diagnostic algorithms to track and assess a persons health status, This can occur with the patient in an ambulatory setting, remotely and in real-time. It also happens unobtrusively so as to eliminate patient compliance issues and ensure data accuracy while reducing healthcare costs and improving outcomes.
